Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | CFO & Secretary | June 01, 2026 | June 03, 2026 |
| Panbela Therapeutics, Inc.SNBP · Entity 11460 | Chief Financial Officer | February 27, 2018 | March 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 162,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 162,000 · Balance 162,000 F1: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.
Panbela Therapeutics, Inc.
Report date February 27, 2018 · Filed March 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2028-02-27 | Direct | 25,000 |
Reported balance
After 2018-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-27 · Grant · Acquired 25,000 · Balance 25,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 21:23 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 162,000 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001490476-26-000002 · form4-06032026_090610.xml · derivative · entry 1 Kellen Scott · CIK 0001490476 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Voting Common Shares · 162,000 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:16 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019290 · rdgdoc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Shares · 225,000 shares Expires 2035-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:59 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000052 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:21 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 10,000 | $3.91 | $39,100.00 |
DisclosureSEC source: 0001235802-23-000070 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,290 Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:46 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000062 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:02 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000075 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:10 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 10,000 | $3.15 | $31,463.00 |
DisclosureSEC source: 0001235802-21-000097 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,290 Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 01:02 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000091 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2031-07-27 F1 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 13:16 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 2,000 | $4.19 | $8,386.60 |
DisclosureSEC source: 0001235802-20-000122 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.1824 to $4.21, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:28 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000054 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| August 19, 2019 Filed Aug 19, 2019 20:24 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 3,000 | $2.43 | $7,290.00 |
DisclosureSEC source: 0001235802-19-000108 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.41 to $2.45, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:30 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 99,750 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000062 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,750 Underlying: Common Shares · 99,750 shares Expires 2029-06-23 F1 · derivative.exercise_date: Vests in eight nearly equal quarterly installments over two years. Read SEC document |
| May 24, 2019 Filed May 28, 2019 11:17 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 4,000 | $2.94 | $11,770.00 |
DisclosureSEC source: 0001235802-19-000044 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:22 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 1,250 | $4.00 | $5,000.00 |
DisclosureSEC source: 0001235802-18-000180 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,290 Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:31 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001437749-18-003651 · rdgdoc.xml · derivative · entry 1 Kellen Scott · CIK 0001490476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-27 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:28 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseWarrant (right to buy) · Derivative | 1,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001437749-18-003127 · rdgdoc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2021-02-20 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase one share of common stock for a combined price of $5.00 per "unit." Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:28 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-003127 · rdgdoc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase one share of common stock for a combined price of $5.00 per "unit." Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 17:11 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001437749-17-005019 · rdgdoc.xml · derivative · entry 1 Kellen Scott · CIK 0001490476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 93,000 shares Expires 2026-12-12 F1 · derivative.exercise_date: On December 12, 2016, the reporting person was granted an option to purchase up to 300,000 shares of common stock. The option became exercisable with respect to 66,000 shares as of December 12, 2016 and with respect to an additional 93,000 shares as of March 17, 2017. The remainder is subject to vesting proportionately based on cash proceeds received by, or contractually obligated to be remitted to, the issuer after June 1, 2016 and before December 31, 2018 from any transaction, excluding certain internal operating-related cash flows. F2 · derivative.underlying_shares: Option vested with respect to 93,000 additional shares pursuant to certification by issuer compensation committee. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 17:01 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001437749-16-043350 · rdgdoc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2026-12-12 F2 · balance_after: On December 12, 2016, the reporting person was granted an option to purchase up to 300,000 shares of common stock. The option vests proportionately based on cash proceeds received by, or contractually obligated to be remitted to, the issuer after June 1, 2016 and before December 31, 2018 from any transaction, excluding certain internal operating-related cash flows. The performance criteria was 22% satisfied on the date of grant, resulting in vesting of the option as to 66,000 shares. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 17:01 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001437749-16-043350 · rdgdoc.xml · derivative · entry 1 Kellen Scott · CIK 0001490476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-12-12 F1 · derivative.exercise_date: Options scheduled to vest in eight equal installments on the last day of each calendar quarter, starting March 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.